Palvella Therapeutics PVLA Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's derivative liabilities (non-current)?
- Palvella Therapeutics (PVLA) reported derivative liabilities (non-current) of $2.16M in Q1 2026.
- How has Palvella Therapeutics's derivative liabilities (non-current) changed year-over-year?
- Palvella Therapeutics's derivative liabilities (non-current) increased by 25.3% year-over-year, from $1.72M to $2.16M.
- What is the long-term trend for Palvella Therapeutics's derivative liabilities (non-current)?
- Over 2 years (2023 to 2025), Palvella Therapeutics's derivative liabilities (non-current) has grown at a 41.9% compound annual growth rate (CAGR), from $1.01M to $2.04M.
- What does derivative liabilities (non-current) mean?
- This represents the fair value of financial instruments, such as warrants or embedded options, that are classified as liabilities and are not expected to be settled within the next twelve months. These instruments often arise from complex financing arrangements or equity-linked debt structures. Changes in this balance reflect shifts in the company's valuation and the potential for future dilution or cash settlement requirements.